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Breast cancer continues to remain the most lethal malignancy in women across the world. This study reviews some of the
epidemiological similarities and diﬀerences in breast cancer between white European women and black African women with the
aim of optimising care for women with breast malignancy across the world. The incidence of breast cancer is lower among African
women than their European counterparts. Majority of women in Europe are postmenopausal when they present with breast
cancer; however, the peak incidence among African women is in the premenopausal period. Ductal carcinoma is the commonest
type of breast cancer among women in Africa and Europe. However, medullary and mucinous carcinomas are more common in
Africa than in Europe. While European women usually present at an early stage especially with the advent of screening, African
women generally present late for treatment resulting in lower survival rates. There should be more research at the molecular level
among African women to identify genetic factors that may contribute to the risk of developing breast cancer. There should also be
improvement in the health care system in Africa in order to optimise care for women with breast cancer.
1.Introduction
Breastcancercontinuestoremainthemostlethalmalignancy
in women across the world. In 2008, approximately 1.4
millionwomenwerediagnosedwithbreastcancerworldwide
with corresponding 460000 deaths [1]. Of these, approxi-
mately 450000 women were diagnosed with the disease in
Europe with a corresponding 140000 deaths, while 68000
women were reportedly diagnosed with the disease in Africa
with a corresponding 37000 deaths [1]. A number of studies
have suggested that there are epidemiological diﬀerences
between breast cancers among women in Europe and Africa.
R i s kf a c t o r ss u c ha sm e n o p a u s e ,o r a lc o n t r a c e p t i v eu s e ,
cigarette smoking, and family history of breast cancer have
been shown to have diﬀerent relations to breast cancer
among blacks and whites [2]. This paper aims to uncover
some of the epidemiological similarities and diﬀerences in
breast cancers between white European women and black
African women.
2. Incidence
Breast cancer is a leading cause of death among women
in West Africa with an approximately 30000 new cases
in 2008 and more than 16000 deaths [1]. The incidence
appears to be signiﬁcantly lower in Eastern Africa with
approximately 18000 new cases and a corresponding 10000
deaths during the same year [1]. In Western Europe, the
incidence is ﬁve times higher than that in West Africa. Fur-
thermore, approximately 40000 deaths from breast cancer
wererecordedin2008[1].TheincidenceissimilarinCentral
and Eastern Europe with approximately 115000 new cases
and more than 47000 deaths in 2008 [1]. The incidence
has also been shown to be signiﬁcantly higher among
women of European origin in the United States of America.
Fejerman and colleagues reported that Greater European
ancestry is associated with increased risk of breast cancer
[3]. They recorded a statistical signiﬁcance when women2 Journal of Cancer Epidemiology
with 51% to 75% and 76% to 100% European ancestry were
compared with women with 0% to 25% European ancestry
[3].
3. Age at Presentation
The mean age at presentation varies between Africa and
Europe. It has been reported that the mean age is 48 years
in Africa and approximately two-thirds are premenopausal
[4, 5]. On the contrary, the majority of women present at
postmenopause in Europe [6–8]. In the United Kingdom,
the median age at presentation for Black women is similar
to African women at 46 years compared to 67 years in white
British women [9]. African-American women have also been
found to present at a signiﬁcantly younger age than their
Caucasian counterparts [10, 11]. The factors responsible for
this are not fully understood, although it could be due to
the breast cancer genes (BRCA 1 and 2) and their variants
[12].
4. Hormones
It is thought that diﬀerences in the epidemiology of breast
canceramongracescouldpartlybeattributedtoendogenous
hormones. Pinheiro and colleagues analysed the association
between race and hormone levels among premenopausal
African-American, Asian-American, and Caucasian women
in the United States [13]. In comparison to Caucasians,
African-American women had 18% higher levels of oestra-
diol (P<0.01), 17% higher free oestradiol (P<0.01) and
11% higher IGF-1 (P<0.01) [13]. Of signiﬁcant note is
the fact that premenopausal African-American women were
found to have 11% lower levels of sex hormone binding
globulin (SHBG) [13] as it is well known that SHBG is
associated with a decrease in the risk of breast cancer risk
[14]. In another study, African-American women had 17.4%
and 25% higher levels of follicular and luteal phase oestra-
diol concentrations, respectively, than Caucasian women
[15]. These ﬁndings may explain the higher incidence of
premenopausal breast cancer among women of African
origin.OfparticularinterestisthatpostmenopausalAfrican-
American women also have higher levels of oestradiol than
white women but, in contrast to premenopausal level,
they have higher levels of SHBG [16]. Unfortunately, there
is paucity of data on hormone levels of premenopausal
nonmigrant African women.
5. Histopathology of Breast Cancer
Histologically, ductal carcinoma is the commonest type of
breast cancer among women in Africa and Europe with
similarfrequency[5,17].However,medullaryandmucinous
c a r c i n o m a sa r em o r ec o m m o ni nA f r i c at h a ni nE u r o p e .I n
addition, more women have grade 3 tumours in Africa than
in Europe. In Tanzania, for example, 56.4% have tumours
with histological grade 3 [5], while, in Nigeria, 45.1% have
grade3tumour[18]. On the contrary, only 15.8% of Finnish
w o m e nh a v eag r a d e3t u m o u r .M o s tw o m e ni nE u r o p e
p r e s e n tw i t hag r a d e1o r2t u m o u r[ 17]. African-American
women are also considerably more likely to have high
grade nuclear atypia, grade 3 tumours, increased number of
positive nodes, and more necrosis than white women [19–
21]. Black British women have been shown to have higher
rates of grade 3 tumours and lymph-node-positive disease
than white British women [9]. This may explain why the
progression of breast cancer is more aggressive in African
w o m e nt h a ni nE u r o p e a nw o m e n .
Gene expression analysis has been used to classify breast
cancer into various subtypes. These include luminal A,
luminal B, basal-like, HER2+/ER−, and unclassiﬁed. Basal-
like breast tumours occur at a signiﬁcantly higher rate
amongpremenopausalAfrican-Americanpatientscompared
with postmenopausal African-American and non-African-
American patients [22].
6. Stage at Presentation
There is a signiﬁcant diﬀerence in staging at the time of
presentation between European women and their African
counterparts. Most women in Africa present when the
disease is at an advanced stage. In a study in East Africa,
more than 70% of the patients presented at stage III or IV
[5]. In studies in Libya and Nigeria, more than half of the
patients presented at stage III or IV [17, 18]. However, in
Europe, women are more likely to present when the disease
is still in its early stage [23]. In a Nigerian study, as high as
39% of the patients had fungating tumours while 13% had
clinical evidence of systemic metastasis [4]. The reason for
the advanced presentation in Africa could be due to lack
of health care coverage especially in remote rural areas and
poverty as healthcare is not free in most countries. On the
contrary, in most European countries, healthcare is easily
accessible and free. In addition, public awareness is high and
screening is available in most European countries.
7. Breast Cancer Genes(BRCA1 andBRCA2)
Breast cancer susceptibility genes 1 and 2 (BRCA1 and
BRCA2) are tumour suppressor genes, and mutation of these
genes has been shown to be associated with an increased
risk of developing breast cancer. These genes have been
demonstrated to contribute to an increased risk of breast
cancer among European women. In a study in Sweden,
BRCA mutations were more frequent among case subjects
with one ﬁrst- or more than one ﬁrst- or second-degree
relative with breast or ovarian cancer (P<0.001) than
among subjects without this degree of family history [24].
In addition, BRCA mutations were statistically signiﬁcantly
more common among women with bilateral breast cancer
thanamongwomenwithunilateralbreastcancer(P = 0.002)
[24]. Research has even suggested that the age of onset
of breast cancer tends to be younger in BRCA1 mutation
carriers than BRCA2 mutation carriers [25]. Unfortunately,
muchresearchhasnotbeendoneonthepossibilityofgenetic
predisposition to breast cancer among native African women
in the African continent.Journal of Cancer Epidemiology 3
8. Management
As many breast cancer cases are detected early in Europe,
many of the women could have breast conserving surgery
(BCT). In Poland, for example, the number of tumours
detected with diameters ≤5cm increased from 57% in 1984
to 81% in 2003 [26]. On the contrary, in Africa, only 52%
of the patients have tumour size below 6cm [5]. As a
result, most women in Africa have mastectomy and adjuvant
hormonal therapy or chemotherapy and many others only
receive palliative care because the tumour is advanced and
inoperable.
9. Discussion
Breast cancer is increasing in regions that until recently
had low rates of the disease. However, the incidence of
the malignancy is still low in Africa compared to the
incidence in Europe. This has largely been attributed to
a protective reproductive history including late menarche,
early menopause, high parity with prolonged breastfeeding,
irregular menses, and fewer ovulatory cycles [27]. However,
ithasbeenreportedthatAfricanwomentendtopresentatan
earlierageandthediseaseappearsto bemoreaggressivethan
in their European counterparts. This could be due to certain
genetic predisposition. Unfortunately, much genetic work
has not been done on nonmigrant African women, although
some research has been done in their African-American
counterparts. In an American study, most African-American
patients had mutations in BRCA2 while most mutations in
the white cohort were in BRCA1 [28]. The study further
stated that almost half of the African-American women had
variants of uncertain signiﬁcance, compared to only 12% of
the white cohort [28]. In addition, Black women in Europe
exhibit similar pattern of disease to African women than
to white European women suggesting that genetics may be
playing a more signiﬁcant role. The higher prevalence of
basal-like breast tumours and a lower prevalence of luminal
A tumours could also contribute to the poor prognosis in
youngAfrican-Americanwomenwithbreastcancer.Itwould
be of immense beneﬁt if there could be research into the
genetics of breast cancer among African women in various
regions of the African continent. Such research might even
reveal mutations that are currently unknown.
African-Americans have the highest rates of pre-
menopausal breast cancer, and it has been suggested that
this might be linked to hormonal levels such as oestrogen
[29]. Oestrogen stimulates cell division, and, therefore, the
higher the exposure of a woman to oestrogen, the higher
the rates of cell division in the breast. A high rate of
cell division predisposes humans to DNA copying error,
resulting in higher risk of cancer. Studies have shown that
African-American women have higher levels of oestradiol,
free oestradiol, and IGF-1, all of which have been attributed
to a higher risk of breast cancer. SHBG reduces the risk
of breast cancer and the fact that postmenopausal African-
American women appear to have a higher level of SHBG may
explain why Black women both in and out of Africa are at a
lower risk of breast cancer after menopause. However, other
risk factors may combine to increase the risk of breast cancer
in postmenopausal Caucasian women.
The high mortality from breast cancer in Africa could
be attributed to poverty. In most parts of Africa, health
care is not free, and, as a result, women delay before
presentation to hospital. It is not uncommon for them to
have used unorthodox medicine before eventually visiting
the hospital. In many instances, the disease would have
reached an advanced stage. This is in contrast to most
European countries where health care is not only free, but
also regular screening is available to women of certain ages.
This increases the probability of detecting breast cancer at
a very early stage. In the United Kingdom, for example,
women aged 50–70 years are invited for breast screening
with mammography every three years [30]. In addition, the
National Institute of Clinical Excellence (NICE) has stated
that women who are known to have a genetic mutation
should be oﬀered annual MRI surveillance if they are BRCA1
and BRCA2 mutation carriers aged 30–49 years and TP53
mutation carriers aged 20 years or older [31]. In France,
regional breast cancer screening programmes are being
oﬀeredtowomenaged50–74years.Unfortunately,thisisnot
the practice in many African countries.
The poor health care system in Africa also aﬀects the
management of breast cancer patients. Many women in
Africa are unable to undergo breast conserving surgery
(BCT) because of lack of radiotherapy facilities. To perform
a breast conserving surgery, radiotherapy would be required
aftersurgery[32].Asaresult,asigniﬁcantnumberofAfrican
women with breast cancer have to undergo mastectomy. This
is in contrast to Europe where many breast cancer patients
a r ea b l et oh a v et h e i rb r e a s tc o n s e r v e d[ 33] because of the
availability of radiotherapy facilities. In Africa, mastectomy
rate is more than 85% [4], compared to just 30% in Europe
[33, 34]. In fact, in the UK, more than 70% of screen-
detectedbreastcancerpatientshaveBCT[34].Thereareonly
4 radiotherapy centres in Nigeria, with a population of 160
million, compared to the UK that has a population of 60
million and more than 70 radiotherapy centres.
There must be political will on the part of African leaders
to adequately fund the health care system. To optimise
the management of breast cancer patients, there must be
access to radiotherapy facilities and cytotoxic drugs must
be readily available. Imaging facilities such as computerised
tomography (CT) and magnetic resonance imaging (MRI)
must be readily available at no cost to the patient or at an
aﬀordable rate.
As it appears that Black women, both within and outside
Africa, have a higher incidence of premenopausal breast
cancer, it might be worth considering lowering the age
at which Black women are ﬁrst invited for screening in
countries that have a breast cancer screening programme so
as to detect malignant changes as early as possible.
10. Conclusion
The epidemiological similarities and diﬀerences in breast
cancer among women in Europe and Africa have been4 Journal of Cancer Epidemiology
reviewed. There should be more research at the molecular
level among African women to identify genetic factors that
may contribute to the risk of developing breast cancer. There
should also be improvement in the health care system in
Africa in order to optimise care for women with breast
cancer.
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